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Lipopolysaccharide (LPS) from Gram (-) bacteria induces inflammatory cholestasis by 
impairing the expression/localization of transporters involved in bile formation (e.g., 
Bsep, Mrp2). Therapeutic options for this disease are lacking. Ursodeoxycholic acid 
(UDCA) is the first choice therapy in cholestasis, but its anticholestatic efficacy in this 
hepatopathy remains to be evaluated. To asses it, male Wistar rats received UDCA for 5 
days (25 mg/Kg/day, i.p.) with or without LPS, administered at 8 a.m. of the last 2 days 
(4 mg/Kg/day, i.p.), plus half of this dose at 8 p.m. of the last day. Then, plasma alkaline 
phosphatase (ALP), bile flow, basal and taurocholate-stimulated bile acid output, total 
glutathione output, and total/plasma membrane liver protein expression of Bsep and 
Mrp2 by confocal microscopy were assessed. mRNA levels of both transporters were 
assessed by Real-time PCR. Plasma pro- inflammatory cytokines (IL-6 and TNF-α) were 
measured by ELISA. Our results showed that, UDCA attenuated LPS-induced ALP 
plasma release and the impairment in the excretion of the Bsep substrate, taurocholate. 
This was associated with an improved Bsep expression at both mRNA and protein 
levels, and by an improved localization of Bsep in plasma membrane. UDCA failed to 
reduce the increase in plasma pro-inflammatory cytokines induced by LPS and Mrp2 
expression/function. In conclusion, UDCA protects the hepatocyte against the damaging 
effect of bile acids accumulated by the LPS-induced secretory failure. This involved an 
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Inflammatory cholestasis is a frequent, often severe clinical condition, characterized 
by the impairment in bile production induced by pro-inflammatory cytokines [1]. Sepsis-
induced cholestasis is prototypical of this kind of cholestasis [2]. It is an early, common 
complication found in more than 20% of hospitalized, icteric septic patients [3], and a 
main cause for admission and pediatric mortality in intensive care units [4].
Sepsis-induced cholestasis is causally associated with endotoxin, a 
lipopolysaccharide (LPS) from the Gram (-) bacterial wall. LPS is a pathogen-associated 
molecular pattern (PAMP) that is sensed by pattern-recognition receptors in 
macrophages, mainly Kupffer cells in liver [5]; LPS binding is followed by NLRP3 
inflammasome activation, and the further release of pro-inflammatory cytokines [6]. 
These cytokines induce transcriptional and post-transcriptional impairment in the 
expression of hepatocellular carriers of bile acids and glutathione (GSH), the main 
osmotically active solutes driving bile formation [1, 2, 7]. LPS injection to rats induces 
downregulation of the bile acid basolateral importers Na+/taurocholate cotransporting 
polypeptide (Ntcp) and organic anion-transporting polypeptide (Oatp) 1, 2, and 4 [8]. In 
the canalicular pole, the expressions of multidrug resistance-associated protein 2 (Mrp2, 
aka Abcc2), the bilirubin glucuronide/GSH transporter, and bile salt export pump (Bsep, 
aka Abcb11), the main bile acid carrier, are also impaired [9], via transcriptional and 
postranscriptional mechanisms, [10]. Bsep and Mrp2 also suffer endocytic internalization 
in endotoxemia [11, 12], which may lead to their delivery to degradation compartments 
[11].
At present, there is no specific treatment for sepsis-induced cholestasis. However, it 
is imperative to find it, since cholestasis potentiates the development of the final septic 
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shock [13]. Actually, the increased levels of bile acids occurring in this condition are 
predictive of sepsis-associated mortality [14], since bile acids act as danger-associated 
molecular patterns (DAMPs) which, like PAMPs, activate the NLRP3 inflammasome, 
and synergize with LPS the cytokine release [13].
Ursodeoxycholic acid (UDCA) treatment is the only disease-modifying therapy in 
primary biliary cholangitis [15, 16], and the “first choice” therapeutic approach for most 
cholestatic hepatopathies [17]. UDCA may counteract both inflammation and bile acid-
induced liver damage via multiple mechanisms, including i) protection against bile acid-
induced necrotic and apoptotic cell death, ii) induction of hepatocellular metabolic 
changes that reduces bile acid levels and toxicity, and iii) anti-inflammatory and 
immunomodulatory properties [17-19]. Some of these effects seem to involve its role as 
an activating ligand of the nuclear receptors pregnane X receptor (PXR) [20] and 
farsenoid X receptor (FXR) [21], two transcription factors that regulate genes involved in 
synthesis and disposal of bile acids [22, 23]. However, the most relevant UDCA effects 
in vivo are FXR-independent and postranscriptional in nature [24]. For example, UDCA 
favors reinsertion of canalicular transporters that have been endocytosed after the 
cholestatic insult [25, 26].
Despite all these alleged protective mechanisms may be of benefit to preserve biliary 
secretory function in sepsis-induced cholestasis, the anticholestatic efficacy and action 
mechanisms of UDCA in this hepatopathy have not been evaluated yet. This study 




2. Materials and methods
2.1 Chemicals. LPS from Salmonella typhimurium, UDCA, bromosulfophthalein (BSP), 
3α-hydroxysteroid dehydrogenase, NADPH, β-NAD, and GSH reductase were 
purchased from Sigma-Aldrich (St. Louis, MO). Sodium taurocholate (TC) was 
purchased from Santa Cruz Biotechnology (Dallas, Texas, U.S.A.). All the other 
reagents were of the highest analytical grade available from commercial sources.
2.2 Animals and treatments. Animals were obtained from our bioterium and received 
humane care according to the “Guide for the Care and Use of Laboratory Animals” 
published by the NIH (publication 25-28, revised in 1996). Animal experiments were 
approved by the Bioethical Committee for the Care and Use of Laboratory Animals of 
the Faculty of Biochemical and Pharmaceutical Sciences of the National University of 
Rosario (Resolution N° 489/2015). Adult (90 days), male Wistar rats weighing 300-350 g 
were used throughout. Animals were maintained on a standard diet and water ad 
libitum, under a constant 12 hour-light/12 hour-dark cycle. During the experiments, 
animal welfare was warranted by monitoring vital signs (heart and respiratory rates) and 
pain sensitivity (paw-withdrawal latency). All the treatments and the experiments with 
animals were performed in The Institute of Experimental Physiology (IFISE).
Rats were randomized in 4 experimental groups:
LPS group. The animals received UDCA vehicle (propylene glycol) for 5 days. At 8:00 
am of the last two day, the animals were given a single, i.p. injection of LPS (4 
mg/Kg/day, i.p., dissolved in saline) and, at 8:00 pm of the last day, a third dose of LPS 
of 2 mg/Kg was injected. 
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UDCA+LPS group. The animals received a daily dose of UDCA (25 mg/Kg/day, i.p., 
dissolved in propylene glycol) for 5 days [27-29]; this dosage is within the therapeutic 
range used in humans to treat cholestatic diseases [30]. Over the last two days, LPS 
was given as stated in the previous group.
Control group. The animals received UDCA and LPS vehicles throughout.
Experiments were carried out 12 hours after the last LPS (or LPS vehicle) 
administration.
2.3 Surgical procedures. Rats were anesthetized with Ketamina and Xylazina (100 
mg/kg p.c. and 3,5 mg/kg p.c., respectively) and thus maintained throughout. Body 
temperature was measured with a rectal probe, and maintained at 37ºC with a heating 
lamp. The femoral vein and the common bile duct were cannulated with PE50 and PE10 
polyethylene tubing, respectively (Intramedic, Clay Adams, Parsippany, NJ). At the end 
of each experiment, animals were sacrificed by exsanguination, and the liver was 
removed and weighed.
2.4. Experimental and analytical procedures. A sample of basal bile was collected for 
10 min to monitor basal bile flow, which was determined gravimetrically, assuming a 
density of 1 g/mL. Basal bile was assayed for both total bile acids and glutathione, the 
two main biliary solutes acting as driving force for bile formation [31]. Total bile acids 
were measured by using the method of the α-hydroxysteroid dehydrogenase [32], 
whereas total glutathione content was assessed by using the recycling method of Tietze 
[33], as modified by Griffith [34]. Once finished the bile collection period, animals were 
sacrificed by exsanguination, and the liver removed. The activity of the cholestasis 
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enzyme alkaline phosphatase (ALP; EC 3.1.3.1) was assessed in plasma by using a 
commercial kit (Wiener Lab., Rosario, Argentina). A blood sample from the tail vein was 
also obtained 2 hs after the second LPS injection using heparin as anticoagulant, to 
measure plasma levels of the inflammatory cytokines IL-6 and TNF-α, by using 
commercial kits (Rat IL-6 ELISA Kit from Life Technologies and Rat TNF alpha ELISA 
Ready-SET-Go!® from eBioscience, respectively).
2.5. Bsep/Mrp2 localization and protein expression. Liver samples were sectioned 
and frozen in isopentane precooled at -70°C in freezer, and stored at this temperature 
for further immunofluorescence and confocal microscopy analysis (LSM880, Carl Zeiss 
LLC, Thornwood, NY, USA). Liver sections were fixed and stained as described [35, 36], 
followed by overnight incubation with a rabbit anti-rat Bsep (1:200; Kamiya Biomedical 
Co., Seattle, WA, USA), or with a mouse anti-rat Mrp2 (1:200; [M2III-6], Alexis 
Biochemicals, San Diego, CA, USA), followed by incubation with a Cy2-conjugated 
donkey anti-rabbit IgG or a Cy2-conjugated donkey anti-mouse IgG, respectively (1:200, 
1 h; Jackson ImmunoResearch Laboratory, West Grove, PA). The tight junctional-
associated protein Occludin was used to delimitate the border of the bile canaliculi. 
Occludin was labeled with a mouse anti-rat Occludin (when Bsep immunostaining was 
carried out, 1:200, overnight; Invitrogen) or with a rabbit anti-rat Occludin (when Mrp2 
immunostaining was carried out, 1:200, overnight; Zymed, San Francisco, USA), 
followed by incubation with a Cy3-conjugated donkey anti-mouse or a Cy3-conjugated 
donkey anti-rabbit (1:200, 1 h, Jackson ImmunoResearch Laboratory, West Grove, PA.), 
respectively. To ensure comparable staining and image capture performance for the 
different groups belonging to the same experimental protocol, liver slices were prepared 
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on the same day, mounted on the same glass slide, and subjected to the staining 
procedure and confocal microscopy analysis simultaneously. Quantification of the 
degree of Bsep and Mrp2 endocytic internalization was performed on confocal images 
using ImageJ 1.34m (National Institutes of Health), as described elsewhere [37]. For this 
purpose, intensity of fluorescence associated with the transporters along an 8-µm line 
perpendicular to the canaliculus (from -4 µm to 4 µm of the canalicular center). For each 
section, data from at least 15 different canaliculi were collected, and used for statistical 
comparison. At least two animals per group were used to assess the localization profile 
of the transporters, and the number of photographs analyzed per animal was 4-7. Each 
measurement was normalized to the sum of all intensities of the respective 
measurement. For quantification of total Bsep- and Mrp2-associated fluorescence 
intensity as a measure of protein expression, all sections were stained in a serial 
manner, and the same settings of confocal parameters were applied for each slide. The 
images were then loaded into ImageJ, the region of interest (ROI) traced, grey level 
intensities analyzed, and background subtracted systematically [38]. The images were 
then analyzed with ImageJ/FIJI image processing software, and the total fluorescence 
intensity of Bsep and Mrp2 were calculated. The results were then referred to control 
values.
2.6. Bsep/Mrp2 transport function. Transport activity of Bsep and Mrp2 was assessed 
by using sodium TC and BSP as model substrates. Based upon its relative affinity for 
Bsep as compared to other naturally occurring bile acids, TC is considered one of the 
best substrate to assess Bsep-mediated transport [39]. Regarding BSP, this cholephilic 
dye is taken up by Oatps and excreted with high affinity via Mrp2 after GSH conjugation 
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by glutathione-S-transferases [40, 41]; its Mrp2-mediated transfer but not the 
conjugation step is the rate-limiting one of its plasma-to-bile transport [42].
TC was administered in single, i.v. doses of 8 µmol/100 g of b.w., and bile samples 
were then collected in 2-minute intervals over the next 10 minutes; after this time the 
exogenously administered TC was completely cleared in control animals.  Bile salts 
were measured in bile with the α-hydroxysteroid dehydrogenase method [32], and TC 
excretion was calculated by assuming that all the excess in biliary excretion rate of bile 
acids over the basal one after TC injection is fully due to TC excretion. This assumption 
was confirmed by ancillary experiments in which biliary bile salt composition was 
analyzed by HPLC (Waters, Mildford, MA), as reported previously [43]; only increments 
in TC but not in other biliary bile salts in the rat were recorded after TC administration 
(data not shown).
BSP was administered in single, i.v. doses of 3 mg/100 g of b.w. Bile samples were 
then collected in 5-minute intervals over the next 60 minutes, a time period sufficient to 
virtually fully depurate the dye in control animals. BSP in bile was determined 
spectrophotometry at wavelength of 580 nm, after appropriate dilution with 0.1 N NaOH 
[44].
2.7 RNA isolation and real time reverse transcriptase polymerase chain reaction 
(RT-PCR). After treatment, total RNA was isolated from liver tissue using TRIzol® 
reagent (Invitrogen). Yield of extracted RNA was evaluated spectrophotometrically at 
260 nm, through the following conversion: 1 OD = 40 µg/µL of RNA. Purity and integrity 
of RNA was assessed by the A260/A280 ratio and 1,2 % agarose gel electrophoresis 
under denaturing conditions (110 V, 40 min), and using SYBER-SAFE as marker. The 
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gel was then observed in a UV transilluminator.  A260/A280 ratios should be between 
1.8 and 2.2, whereas the 28S rRNA band should be about twice the intensity of the 18S 
band, and higher molecular weight bands indicative of DNA contamination should be 
absent. The first-strand cDNA was synthesized from 1 μg of total RNA using Superscript 
III Reverse Transcriptase (Invitrogen) and random primers according to the 
manufacturer’s suggested protocol. Primers for Abcb11 were designed using the 
"Primer-BLAST" program [45], and sequences of primer pairs for Abcc2 were as 
previously described [46] (Table 1). Real time PCR reactions were performed on a 
Mx3000P System (Stratagene, La Jolla, CA) with Platinum Taq DNA Polymerase 
(Invitrogen) and SYBR Green quantification. The thermocycling regime was 2 min at 95 
°C for initial denaturation; and then 40 cycles of 95 °C for 15 s, 55 °C for 30 s, and 72 °C 
for 30 s; and the final step was 1 min at 95 °C, 30 s at 55°C and 30 s at 95 °C. Results 
for Abcb11 and Abcc2 mRNA were normalized to the expression of 18S rRNA as the 
housekeeping gene by using the 2-Δ Δ Ct method 47]. The primers for 18S rRNA were 
those previously designed by Ruiz et. al. [46] (Table 1). The specificity of each reaction 
was verified with a dissociation curve using a temperature range from 55 ºC to 95 ºC, 
with continuous fluorescence measurements.
2.8. Statistical analysis. Data are expressed as means ± SEM. Statistical analysis was 
carried out by using ANOVA or Student t test, unless another statistical test has been 
determined to be more appropriate. The variances of the densitometric profiles of Bsep 
and Mrp2 localization were compared with the Mann-Whitney U test [48]. Values of 




3.1. Blood and biliary parameters of inflammation and cholestasis. As shown in 
Table 2, LPS significantly increased ALP plasmatic levels, a plasma membrane enzyme 
that is induced in both hepatocytes and cholangiocytes, and released from the cell 
surface into blood by detergent bile acids that are retained in cholestasis [49] UDCA 
pretreatment reduced partially this increase, suggesting protection against intrahepatic 
bile acid building and/or bile acid-induced plasma membrane damage.
As expected, plasma levels of the pro-inflammatory cytokines TNF-α and IL-6 were 
both increased by LPS. UDCA pretreatment was unable to significantly reduce these 
increments; only a tendency was observed for TNF-α, but it did not reach statistical 
significance (Table 2). This suggests that the beneficial effects of UDCA are not mainly 
due to an attenuation of the inflammatory response evoked by LPS.
As shown in Table 3, LPS significantly reduced bile flow, and coadministration of 
UDCA did not attenuate this decrease. UDCA did not significantly increase the basal 
biliary excretion rate of both bile acids and glutathione when coadministered with LPS. 
However, when a bolus of TC was administered so that to acutely challenge the Bsep-
mediated secretory pathway, the decrease in both bile flow and bile acid output induced 
by LPS was partially counteracted by UDCA coadministration; this suggests that Bsep 
transport function, and hence bile acid-dependent bile flow, are indeed improved by 
UDCA, but it is required to force the transport system with higher levels of intracellular 
bile acids for this recovery to become apparent.
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3.2 Bsep and Mrp2 transport function. Bsep and Mrp2 transport function was 
assessed by recording the changes over time in the biliary excretion of TC and BSP, 
respectively, following a bolus injection of these compounds 
As shown in Fig. 1, TC was transported less efficiently by LPS-treated rats, as 
indicated by the 45% lower value of accumulated biliary excretion of this compound, as 
compared to controls after 4 min of TC injection. UDCA prevented partially this 
decrease, reaching a 40% higher value of cumulative TC excretion as compared to LPS 
group.
As depicted in Fig. 2, BSP was also transported less efficiently by LPS-treated rats, 
as suggested by the 30% lower value of accumulated biliary excretion of the dye as 
compared to controls after 60 min of its injection. This impairment was however not 
counteracted by UDCA, since cumulative BSP excretion in the co-treated rats with 
UDCA was similar to that of LPS alone (Fig. 2, upper panel).
3.3. Protein expression and localization of Bsep and Mrp2. As shown in Table 4, 
total Bsep and Mrp2 protein content, as assessed by measuring the total Mrp2- and 
Bsep-associated green fluorescence in the fields, was significantly impaired by LPS, 
with reductions of 59% and 31%, respectively.
Figure 3 A shows confocal images of Bsep (green) and the canaliculus border marker, 
occludin (red). In control livers, transporter-associated fluorescence was confined to the 
canalicular space. In LPS-treated rats, the carrier relocalized from the canalicular space 
to the pericanalicular, as indicated by the increased fluorescence at a greater distance 
from the bile canaliculus, and co-treatment with UDCA counteracted this redistribution. 
Figure 3 B shows the analysis of the distribution profiles of transporter-associated 
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fluorescence along a line perpendicular to the canaliculus. LPS-treated livers showed a 
statistically significant (P<0.05) wider profile with increased fluorescence at a greater 
distance from the canalicular membrane, a finding consistent with endocytic retrieval of 
these transporters into the intracellular compartment (Table 5) On the other hand, in 
livers from the LPS+UDCA co-treated group, the distribution of both Bsep and Mrp2 was 
almost identical to that in control livers (P>0.05). Analysis of the distribution profiles of 
the tight junctional protein occludin as a marker of the canalicular edge demonstrates a 
conserved width of the canaliculi in all the experimental groups, thus ruling out the 
influence of changes in this parameter on the Bsep distribution profiles. These data 
demonstrate that UDCA protects against LPS-induced retrieval of Bsep. Essentially the 
same results were obtained when the distribution pattern of Mrp2-associated 
fluorescence was assessed, with re-localization of Mrp2 outside the limits of the 
canaliculus that is reversed by UDCA co-treatment (Fig. 4).
3.4. Bsep and Mrp2 mRNA expression. RT-PCR analysis shows that both Bsep and 
Mrp2 mRNA abundance in rat livers from LPS-treated rats was markedly decreased by 
85% and 75%, respectively (Table 6). UDCA co-treatment to LPS-treated rats 
normalized mRNA expressions of both transporters.
4. Discussion
UDCA has been suggested as a rationale alternative to treat sepsis-induced 
cholestasis due to its multiple anticholestatic mechanisms [50], and because it is often 
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successful as the first-choice therapy for most cholestatic disorders [17]. However, 
several authors agree that the available experimental and clinical evidence is still 
insufficient [50-52]. Therefore, we have provided here for the first time experimental 
evidence that UDCA bears multiple anticholestatic effects in LPS-induced cholestasis.
First, UDCA helped to preserve hepatocyte integrity against detergent bile acids 
accumulated in cholestasis, as suggested by the reduction in plasma ALP levels 
compared to that in LPS-treated rats (see Table 2). ALP is a membrane-bound enzyme 
that is induced and released into the bloodstream by detergent, endogenous bile acids 
[53], and represents an early indication of membrane damage leading to hepatocellular 
lysis [54]. The counteraction of this pathomechanim by UDCA most likely reflects its 
membrane-protective effects [55] as well as its lack of capability to induce ALP 
expression [56] and to remove ALP from the plasma membrane in cholestatic livers [57].
In agreement with previous works [7, 58], we show here that LPS represses the gene 
expression of the main canalicular bile acid transporter Bsep, leading to downregulation 
of the transporter at a protein level (see Table 4). UDCA upregulated at a transcriptional 
level these otherwise downregulated bile acid transporter (see Table 6), which resulted 
in an ameliorated capability of the hepatocyte to excrete an i.v. load of the model Bsep 
substrate, TC (see Fig. 1).
Improvement of Bsep gene expression by UDCA administration has been reported to 
occur under other cholestatic conditions, as for example in mice exposed to α-
naphtylisothiocyanate [59], but not in normal animals [60] or healthy humans [61]. 
Therefore, the cholestatic context seems to be important for UDCA to improve 
transcriptionally Bsep. Transcriptional Bsep downregulation in LPS-induced cholestasis 
is caused by the cytokines released during the acute-phase response rather than by 
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accumulated bile acids [7]. Cytokine-mediated repression of FXR, the main nuclear 
receptor involved in the maintenance of Bsep levels, has been suggested as a chief 
causal factor [62]. The possibility that UDCA improves Bsep levels by enhancing the 
remnant Bsep transactivating activity of FXR by acting as a FXR ligand is however 
unlikely, because it has a very weak (if any) FXR agonist activity [21]. Apart from 
reducing FXR levels, cytokines impair the DNA binding of FXR to the Bsep IR-1 
responsive element [63, 64]. FXR binds to DNA as a heterodimer with the 9-cis-retinoic 
acid receptor-α (RXRα), and this binding is impaired by cytokines via a c-jun-NH2-
terminal kinase (JNK)-dependent RXR phosphorylation [63, 65]. Although RXRα levels 
are reduced in LPS-induced cholestasis [62, 63], this mechanism may be still operating, 
since a partial replacement of RXRα  by other RXR isoforms not affected by cytokines, 
such as RXRβ and RXRγ, occurs [62]. In line with this, UDCA can inhibit JNK activity in 
hepatocytes exposed to different stressor, such as hydrophobic bile acids [66] and 
lipotoxic fatty acids [67].
Similarly to Bsep, Mrp2 gene transcription was enhanced by UDCA in LPS cholestatic 
rats (see Table 6); this may reflect, again, the capability of UDCA to counteract cytokine-
mediated effects on Mrp2 transcription mechanisms, which is also JNK-dependent in 
nature [63, 65]. In addition, the well characterized inductive effect that UDCA has per se 
on Mrp2 expression [60] may be another contributing factor. Surprisingly, an enhanced 
Mrp2 mRNA levels in the co-treated group did not lead to an improved expression of 
Mrp2 either at the protein level (see Table 4) or at a functional levels, as evaluated by 
assessing the biliary excretion of its exogenous substrate, BSP (see Fig. 2). Similarly, 
biliary excretion of GSH, an endogenous Mrp2 substrate [68], was not ameliorated either 
(see Table 3). Differences in post-transcriptional events (e.g., mRNA processing, 
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steady-state mRNA stability, translational efficacy), as well as in post-translational 
events (e.g., transporter sorting and targeting to the canalicular membrane, protein 
modifications that affect its degradation rate) may be causal factors. Actually, Mrp2 and 
Bsep have marked differences in their post-transcriptional processing, including 
intracellular location at different vesicular pools after LPS-induced endocytic 
internalization [69] and differential intracellular degradation after internalization; Mrp2 
and Bsep both suffer ubiquitination, but then Mrp2 traffics from early endosomes into the 
lysosomal degradation pathway [70], whereas Bsep more likely suffers proteosomal 
degradation [71] Interestingly, higher rates of lysosomal protein degradation occur in 
endotoxemic rats [72], which may have selectively enhanced Mrp2 degradation after 
internalization. The lack of beneficial effect of UDCA on Mrp2 protein expression and 
function should not be necessarily regarded as a drawback, since it helps to retain both 
GSH and bilirubin, two endogenous anti-oxidant compounds that have been shown to 
counteract oxidative stress-induced cholestasis 73, 74], a factor that has been causally 
linked to LPS-induced cholestasis [75, 76].
The improvement in Bsep activity induced by UDCA in LPS-treated rats was apparent 
under conditions of increased bile acid load but not under basal conditions, where 
neither bile flow nor total bile acid excretion was modified (see Table 3). It should be 
born in mind that basal bile acid excretion depends not only on the intrinsic activity of 
Bsep but also on the size of the bile acid pool [77] and the extrusion rate via alternative, 
bile acid basolateral export pumps, such as Mrp3 and Mrp4 [78]; reduction and 
increments in these two last parameters, respectively, decreases canalicular bile acid 
output. UDCA may reduce bile acid pool size, since it decreases absorption of 
endogenous bile acids at the intestinal levels [79] and inhibits Cyp7a1, the rate-limiting 
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enzyme of bile acid synthesis [80]. As for basolateral bile acid extrusion, LPS increases 
the expression of Mrp3 [8, 81], as the result of an adaptive response in cholestasis 
aimed to redirect bile acid flux back to bloodstream for urinary elimination [82]. UDCA 
can further upregulate Mrp3 in the endotoxemic liver [24], and to upregulate Mrp4 as 
well [83]. As a corollary, the lack of improvement in bile acid biliary output by UDCA in 
LPS cholestatic rats under basal conditions should not be regarded as absence of 
anticholestatic effect of UDCA, but as a consequence of other beneficial effects aimed to 
limit bile acid accumulation via both reduced bile acid synthesis and enhanced bile acid 
basolateral efflux [17].
UDCA improved localization of the canalicular transporters Bsep and Mrp2 in their 
membrane domain by counteracting LPS-induced endocytic internalization (see Figs. 3 
and 4, respectively). In line with this, UDCA stabilizes Bsep in the apical membrane of 
MDCK II cells, by preventing its endocytic internalization [84]. Bsep endocytic 
internalization occurs via a clathrin-mediated mechanism from clathrin-rich "non-raft" 
membrane domains under both normal [85] and cholestatic conditions [86], and the 
same holds true for Mrp2, at least under cholestatic conditions [86]. However, both Bsep 
and Mrp2 mainly reside in caveolin/cholesterol-rich "raft" domain, where they are fully 
functional due to its cholesterol dependency [87, 88]. Therefore, they need to be 
transferred to "non-raft" microdomains to be endocytosed [86]. Since UDCA is a 
membranotropic agents that was show to expand and stabilize "raft" structures by 
mimicking cholesterol [89], perhaps it stabilizes Bsep and Mrp2 in these enlarged "raft" 
microdomains, thus preventing their transfer to "non-raft" structures. UDCA may have 
also favored the vesicular trafficking of these transporters back to the canalicular 
membrane after endocytosis. Indeed, UDCA has been shown to stimulate the apical 
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vesicular targeting of both newly-synthesized [90] and pre-existing canalicular 
transporters localized in subapical endosomes [91]. Actually, anticholestatic effects of 
UDCA associated with counteraction of canalicular transporter endocytosis have been 
shown in other experimental models of cholestasis [26, 92].
UDCA attenuated the effects of LPS without reducing expression of TNF-α and IL-6, 
two critical, sentinel cytokines involved in hepatic acute phase response (see Table 2). 
In line with our results, UDCA treatment was not instrumental in reducing the hepatic 
expression of the cytokines TNF-α and IL-1β in cholestatic rats with bile-duct ligation 
[93], a cholestatic model largely associated causally with endotoxemia [94]. Lack of 
effect on cytokine production might, overall, be a rather beneficial UDCA property 
though, since cytokines are involved in the hepatic regenerative response [95], which, in 
the setting of liver cell damage, should be conserved to favor healing.
In conclusion, UDCA can protect the hepatocyte against the damaging effect of bile 
acids accumulated by LPS-induced bile acid secretory failure. This beneficial effect 
involves both transcriptional and posttranscriptional mechanisms, such as improved 
synthesis and function of the main bile acid canalicular transporter, Bsep, and an 
enhanced membrane stability of the carrier. Our results may be of relevance not only for 
sepsis-induced cholestasis, but also for the treatment of other cholestatic liver diseases 
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Figure 1. Upper panel. Cumulative biliary excretion of TC; bile samples were collected 
every 2 min for 10 min, after a single, i.v. dose of 8 µmol/100 g of b.w. of the bile salt. 
Lower panel. Area under the curve (AUC) of cumulative biliary excretion of TC graphs. 
Data are mean value ± SEM for 3-4 individual experiments. *P<0.05 vs. control; #P<0.05 
vs. LPS.
Figure 2. Upper panel. Cumulative biliary excretion of BSP; bile samples were collected 
every 5 min for 60 min, after a single, i.v. dose of 3 mg/100 g of b.w. Lower panel. Area 
under the curve (AUC) of cumulative biliary excretion of BSP graphs. Data are mean 
value ± SEM for 3-4 individual experiments. *P<0.05 vs. control; #P<0.05 vs. LPS.
Figure 3. Effect of UDCA co-treatment on LPS-induced endocytic internalization of 
Bsep. A. Representative confocal images showing co-staining of Bsep (green) with 
occludin (red; used to visualize the bile canaliculus limits), illustrative of the endocytic 
internalization of Bsep induced by LPS (arrows), and its protection by UDCA. The lower 
panels show densitometric analysis of the fluorescence intensity associated with Bsep 
or occludin along a 8 µm line perpendicular to the canaliculus (from -4 µm to +4 µm from 
the canalicular centre), corresponding to the confocal images shown in the upper 




Figure 4. Effect of UDCA co-treatment on LPS-induced endocytic internalization of 
Mrp2. A. Representative confocal images showing co-staining of Mrp2 (green) with 
occludin (red; used to visualize the bile canaliculus limits), illustrative of the endocytic 
internalization of Mrp2 induced by LPS (arrows), and its protection by UDCA. The lower 
panels show densitometric analysis of the fluorescence intensity associated with Mrp2 
or occludin along a 8 µm line perpendicular to the canaliculus (from -4 µm to +4 µm from 
the canalicular center), corresponding to the confocal images shown in the upper 
















Table 1. Sequence of primers for RT-PCR analysis of rat Abcb11 and Abcc2 mRNAs, 
and 18s rRNA.












Table 2. Plasma levels of ALP and the pro-inflammatory cytokines, TNF-α and IL-6.
Control LPS UDCA+LPS
ALP (U/l) 207±23 404±21* 316±24*#
TNF-α (pg/ml) 49±6 133±33* 100±22*
IL6 (pg/mL) N.D. 3604 ±603* 3312 ±558*
*P<0.05 vs. control; #P<0.05 vs. LPS; N.D. = No detectable. n = 6-22.
Table 3. Bile flow and biliary excretion of total bile acids and total GSH.
Control LPS UDCA+LPS
Bile flow
(µl/min per g liver)
Basal 3.4 ± 0.1 2.7 ± 0.1* 2.6 ± 0.1*
TC-stimulated† 5.3 ± 0.2 4.1 ± 0.2* 4.7 ± 0.1#
Bile acid output 
(nmol/min per g liver) 
Basal 128 ± 16 94 ± 13 86 ± 13
TC-stimulated† 226 ± 16 152 ± 7* 216 ± 5#
Total GSH output  
(nmol/min per g liver) 3.7 ± 0.7 1.3 ± 0.2* 0.8 ± 0.1*
†TC-stimulated values correspond to the maximum value obtained after a TC i.v. 








measuring total fluorescence intensity.
*P<0.05 vs. control; #P<0.05 vs. LPS
Table 5. Variance ranges of the fluorescence intensity profiles.  
Control LPS UDCA+LPS
Bsep 0.25 - 1.00 0.66 - 2.29* 0.12 - 1.24#
Mrp2 0.12 - 1.56 0.78 - 2.83* 0.25 - 2.15#
*P<0.05 vs. control; #P<0.05 vs. LPS; n= 15-22.
Table 6. Mrp2 and Bsep mRNA expression by RT-PCR.
Total fluorescence intensity
(% of mean control values)
Control LPS UDCA+LPS
Mrp2 100 ± 7 41 ± 2* 31 ± 2*
Bsep 100 ± 5 69 ± 3* 163 ± 7*#
mRNA levels
(% of mean control values)
Control LPS UDCA+LPS
Mrp2 100 ± 7 25 ± 10* 190 ± 49#
Bsep 100 ± 29 15 ± 3* 79 ± 3#
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*P<0.05 vs. control; #P<0.05 vs. LPS; n = 3-4.
